Oncotarget

Priority Research Papers:

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

Avital Lev _, Amriti R. Lulla, Jessica Wagner, Marie D. Ralff, Joshua B. Kiehl, Yan Zhou, Cyril H. Benes, Varun V. Prabhu, Wolfgang Oster, Igor Astsaturov, David T. Dicker, Wafik S. El-Deiry

Metrics: PDF 139 views  |   HTML 620 views  |   ?  


Abstract

Avital Lev1, Amriti R. Lulla1, Jessica Wagner1, Marie D. Ralff1, Joshua B. Kiehl1, Yan Zhou2, Cyril H. Benes3, Varun V. Prabhu4, Wolfgang Oster4, Igor Astsaturov5, David T. Dicker1 and Wafik S. El-Deiry1

1 Department of Hematology/Oncology, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA

2 Biostatistics Department, Fox Chase Cancer Center, Philadelphia, PA, USA

3 Massachusetts General Hospital, Boston, MA, USA

4 Oncoceutics, Inc., Philadelphia, PA, USA

5 Department of Hematology/Oncology, Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA

Correspondence to:

Wafik S. El-Deiry, email:

Keywords: pancreatic cancer, ONC201, ONC212, AG1024, IGF1-R

Received: July 25, 2017 Accepted: August 17, 2017 Published: September 12, 2017

Abstract

Pancreatic cancer is chemo-resistant and metastasizes early with an overall five-year survival of ~8.2%. First-in-class imipridone ONC201 is a small molecule in clinical trials with anti-cancer activity. ONC212, a fluorinated-ONC201 analogue, shows preclinical efficacy in melanoma and hepatocellular-cancer models. We investigated efficacy of ONC201 and ONC212 against pancreatic cancer cell lines (N=16 including 9 PDX-cell lines). We demonstrate ONC212 efficacy in 4 in-vivo models including ONC201-resistant tumors. ONC212 is active in pancreatic cancer as single agent or in combination with 5-fluorouracil, irinotecan, oxaliplatin or RTK inhibitor crizotinib. Based on upregulation of pro-survival IGF1-R in some tumors, we found an active combination of ONC212 with inhibitor AG1024, including in vivo. We show a rationale for targeting pancreatic cancer using ONC212 combined with targeting the unfolded-protein response and ER chaperones such as GRP78/BIP. Our results lay the foundation to test imipridones, anti-cancer agents, in pancreatic cancer, that is refractory to most drugs.

Author Information

Avital Lev
Primary Contact  _

Amriti R. Lulla

Jessica Wagner

Marie D. Ralff

Joshua B. Kiehl

Yan Zhou

Cyril H. Benes

Varun V. Prabhu

Wolfgang Oster

Igor Astsaturov

David T. Dicker

Wafik S. El-Deiry


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20819